Who
Lawrence Blatt
President and CEO
Company insider
Files Form 4 as: President and CEO, Aligos Therapeutics; Chief Scientific Officer, Intermune.
In numbers
- Trades disclosed
- 65
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $1.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Jan 2006
- Last trade
- 9 Mar 2026
- Last filed
- 11 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Mar 2026filed 11 Mar 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,840 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,840 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —179,800 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,103 at $0.00 | filing |
| 4 Sep 2024filed 6 Sep 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,920 at $0.00 | filing |
| 1 Mar 2024filed 4 Mar 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —965,435 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,352 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,999 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,749 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —450,000 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —323,400 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —80,850 at $0.00 | filing |
| 25 Oct 2023filed 27 Oct 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $40K305,138 at $0.13 | filing |
| 25 Oct 2023filed 27 Oct 2023 | ALGS Aligos TherapeuticsBiotechnology | SEC FORM 4 Code A | $464K610,277 at $0.76 | filing |
| 8 Sep 2023filed 12 Sep 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 15 Mar 2023filed 17 Mar 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —242,500 at $0.00 | filing |
| 7 Jul 2022filed 11 Jul 2022 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —161,700 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —323,400 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,850 at $0.00 | filing |
| 1 Dec 2020filed 3 Dec 2020 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.